The quest for optimizing patient care during and following surgical procedures is unending. Hyperoxia has recently emerged as a topic of considerable debate. In this context, the Vixie trial, a rigorously designed study spearheaded by Dr. Christian Mayhoff and his colleagues, sheds new light on the effects of hyperoxia on postoperative myocardial injury.
The trial had a simple hypothesis: That the administration of higher oxygen concentrations during surgery might influence the incidence of myocardial injury, a complication of significant concern given its association with increased postoperative morbidity and mortality. To this end, the Vixie trial compared the outcomes of patients subjected to two distinct oxygenation strategies—80% oxygen (hyperoxia) versus 30% oxygen (normoxia)—in a randomized controlled setting. The study cohort comprised 600 patients, each with at least one major cardiovascular risk factor.
The primary outcome of interest was the extent of myocardial injury, as gauged by the levels of troponin T post-surgery. Troponin, an indicator of cardiac injury, was measured before surgery and on the first three days thereafter, employing the high-sensitive troponin T assay. This enabled the researchers to construct an area under the curve for troponin concentrations, offering a measure of myocardial injury.
The findings of the Vixie trial were both illuminating and somewhat counterintuitive. Contrary to the initial hypothesis, the trial showed no significant difference in the extent of myocardial injury between the hyperoxia and normoxia groups. Both cohorts exhibited an average area under the curve for myocardial injury of 35 nanograms per liter per day, irrespective of the oxygen concentration administered. This equivalence in myocardial injury incidence, which was 23% across the board, suggests that the level of oxygenation, within the parameters studied, does not exacerbate nor mitigate the risk of postoperative cardiac complications in patients already at risk.
These findings have implications for clinical practice and the broader discourse on patient safety during surgery. At a fundamental level, the Vixie trial challenges prevailing assumptions about the deleterious effects of hyperoxia, suggesting that higher oxygen levels may not inherently predispose patients to greater cardiac risk.
In summary, the Vixie trial sheds light on the intricate process of decision-making concerning hyperoxia, offering a fresh perspective that challenges existing beliefs. Despite this, the fundamental goal of ensuring patient safety throughout the perioperative period remains unchanged. While the study may overturn some outdated concepts, the consensus on avoiding excessive oxygen beyond what is essential for maintaining health is largely uncontested. Consequently, recommendations for clinical practice largely remain consistent.
